

12th July, 2024

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Successful closure of US FDA Inspection at Piramal Pharma's manufacturing facility located at Ahmedabad

Dear Sir / Madam,

This is to inform you that the US FDA conducted a Pre-Approval Inspection ('PAI') of Piramal Pharma Limited's PPDS Ahmedabad facility from 10th July 2024 to 12th July, 2024.

The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.

Successful completion of this wholistic inspection at PPDS Ahmedabad facility, will now enable access to our high-end analytical capabilities to our customers for their clinical and commercial batches from an FDA approved site.

The Company remains committed to maintain the highest standards of compliance.

This is for your information and records.

Thanking you,

Yours truly,
For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com